- Home
- ICHR vs TSHA Comparison
ICHR vs TSHA Comparison
Compare ICHR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICHR
- TSHA
- Stock Information
- Founded
- ICHR 1999
- TSHA 2019
- Country
- ICHR United States
- TSHA United States
- Employees
- ICHR N/A
- TSHA N/A
- Industry
- ICHR Semiconductors
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- ICHR Technology
- TSHA Health Care
- Exchange
- ICHR Nasdaq
- TSHA Nasdaq
- Market Cap
- ICHR 727.6M
- TSHA 728.4M
- IPO Year
- ICHR 2016
- TSHA 2020
- Fundamental
- Price
- ICHR $17.21
- TSHA $2.46
- Analyst Decision
- ICHR Strong Buy
- TSHA Strong Buy
- Analyst Count
- ICHR 6
- TSHA 7
- Target Price
- ICHR $35.20
- TSHA $7.57
- AVG Volume (30 Days)
- ICHR 454.5K
- TSHA 5.2M
- Earning Date
- ICHR 08-05-2025
- TSHA 08-11-2025
- Dividend Yield
- ICHR N/A
- TSHA N/A
- EPS Growth
- ICHR N/A
- TSHA N/A
- EPS
- ICHR N/A
- TSHA N/A
- Revenue
- ICHR $892,122,000.00
- TSHA $7,224,000.00
- Revenue This Year
- ICHR $14.18
- TSHA N/A
- Revenue Next Year
- ICHR $6.66
- TSHA N/A
- P/E Ratio
- ICHR N/A
- TSHA N/A
- Revenue Growth
- ICHR 13.41
- TSHA N/A
- 52 Week Low
- ICHR $15.33
- TSHA $1.05
- 52 Week High
- ICHR $42.70
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- ICHR 44.38
- TSHA 45.90
- Support Level
- ICHR $17.58
- TSHA $2.48
- Resistance Level
- ICHR $19.74
- TSHA $2.66
- Average True Range (ATR)
- ICHR 0.81
- TSHA 0.21
- MACD
- ICHR 0.04
- TSHA -0.06
- Stochastic Oscillator
- ICHR 42.63
- TSHA 10.14
About ICHR Ichor Holdings
Ichor Holdings Ltd is engaged in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The product offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The company also manufactures machined components, weldments, and proprietary products for use in fluid delivery systems. Geographically, the company operates in the United States, Singapore, Europe, and Others, of which a majority of the revenue is generated from Singapore.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.